FORT Update – Palliative Radiation Perspective
Patients with lymphoma have historically been excluded from palliative radiation oncology trials given that these tumors are more radioresponsive than other solid tumors. Though radiation dose/fractionation schemes used to palliate lymphoma are often extrapolated from those used for solid tumors, we highlight here unique considerations for palliation of patients with indolent, non-Hodgkin B-cell lymphomas. FORT (Follicular Radiotherapy Trial), a phase 3 randomized trial, compared whether low-dose radiation therapy (RT) of 4 Gy in 2 fractions was non-inferior in local control to the standard 24 Gy in 12 fractions for patients with either follicular (FL) or marginal zone lymphoma (MZL). Target…
